Medical Marijuana Laws Likely Don't Affect Opioid Overdose Deaths


Contrary to earlier research, investigators found that medical cannabis laws do not reduce deaths caused by opioid overdoses.

Chelsea Shover, PhD

Chelsea Shover, PhD

Contrary to earlier research, a study looking at data through 2017 has indicated that legal medical marijuana does not reduce deaths caused by opioid overdoses.

The current study replicated the results of an earlier study in finding that from 1999 to 2010, there was a negative association between medical marijuana legalization and fatal opioid overdoses—deaths from opioid overdoses decreased 21.1% per 100,000 population. However, when the investigators expanded the data through 2017, the association reversed, and medical marijuana was associated with a 22.7% increase in opioid overdose deaths.

Investigators, led by Chelsea Shover, PhD, a postdoctoral researcher at Stanford University, wrote that “the observed association between these 2 phenomena is likely spurious rather than a reflection of medical cannabis saving lives 10 [years] ago and killing people today.”

Investigators believe that there must have been other factors at play in the states that legalized medical marijuana use early. Keith Humphreys, PhD, professor of psychiatry and behavioral sciences at Stanford University and senior author of the study pointed out that those states had different policies and conditions. He shared the example that in those states fewer people were incarcerated for using drugs.

"If you think opening a bunch of dispensaries is going to reduce opioid deaths, you'll be disappointed," Humphreys said. "We don't think cannabis is killing people, but we don't think it's saving people."

In addition to extending the research through 2017, the research team analyzed the differences between states that have legalized recreational marijuana, those with general medical marijuana laws, and those with restrictive medical marijuana policies that permit only low-THC cannabis.

Investigators wrote that if access to cannabis is the factor associated with decreased opioid overdose deaths, states with recreational marijuana would have the most negative association while those with low-THC restrictions would have less negative, perhaps even positive associations.

Instead, over the timeframe of 1999-2017, states permitting comprehensive medical cannabis use had a 28.2% (95% CI, 1.2-62.4) higher opioid overdose mortality rate. In less restrictive states, laws allowing recreational and medical cannabis use were associated with an opioid overdose death rate decrease of 14.7% (95% CI, −43.6-29.0), while laws with low-THC restrictions were associated with a decrease of 7.1% (95% CI −29.1-21.7).

Shover et al. pointed out that the wide confidence intervals for states with both the least restrictive and most restrictive cannabis use laws include strong positive and negative associations as well as no association.

In addition to pointing out some of the potential confounding factors (state incarceration rates, naloxone availability, access to insurance and services, etc) the authors noted that only about 2.5% of the US population uses medical cannabis. This, they wrote, makes it unlikely that medical marijuana policies have significantly affected population-wide opioid overdose rates.

"There are valid reasons to pursue medical cannabis policies, but this doesn't seem to be one of them," Shover said, adding a call for more research and new policies to reduce deaths from opioid overdoses in other ways.

The study, “Association between medical cannabis laws and opioid overdose mortality has reversed over time,” was published in Proceedings of the National Academy of Sciences.

Recent Videos
Boadie Dunlop, MD, Weighs in on FDA Advisory Vote on Lykos’ MDMA
Bhanu Prakash Kolla, MBBS, MD: Treating Sleep with Psychiatric Illness
Awaiting FDA Decision on MDMA Assisted Therapy, with Bessel van der Kolk, MD
Bessel van der Kolk, MD: The Future of MDMA Assisted Therapy in PTSD
Bessel van der Kolk, MD: What MDMA-Assisted Therapy Taught us About PTSD
Why Are Adult ADHD Cases Climbing?
Getting Black Men Involved in Their Health Care, Clinical Research
Patient Involvement in Advanced HF Treatment, with Ashley Malliett, DMSc, MPAS, PA-C
Aaron Henry, PA-C, MSHS: Regaining Black Male Patient Trust in the Doctor's Office
Depression Screening: Challenges and Solutions at the Primary Care Level
© 2024 MJH Life Sciences

All rights reserved.